...
首页> 外文期刊>Melanoma research >Enrichment of melanoma-associated T cells in 6-thioguanine-resistant T cells from metastatic melanoma patients
【24h】

Enrichment of melanoma-associated T cells in 6-thioguanine-resistant T cells from metastatic melanoma patients

机译:从转移性黑素瘤患者中富集黑色素瘤相关的T细胞抗性T细胞

获取原文
获取原文并翻译 | 示例

摘要

Supplemental Digital Content is available in the text. This study examines whether 6-thioguanine resistant T cells (mutant) from metastatic melanoma patients are enriched for melanoma-associated T cells compared to T cells obtained analogously without thioguanine selection (wild-type). Melanoma-associated antigen pentamer staining was performed on 5 tumour and 9 peripheral blood samples from metastatic melanoma patients. T cell receptor beta chain repertoire was examined via Sanger sequencing of mutant and wild-type in blood and tumour from metastatic melanoma patients at times of tumour progression (n = 8) and via Illumina sequencing in tumour derived T cells and in uncultured T cells (uncultured), wild-type and mutant from blood before and after immune checkpoint blockade (n = 1). Mutant from tumour (3 of 5; P < 0.001), but not blood (0 of 9), were enriched compared to wild-type for binding melanoma-associated antigen pentamers. T cell receptor beta analysis in patients with tumour progression (n = 8) detected increased melanoma associated T cells in mutant compared to wild-type from blood (Monte Carlo P = 10~(?7)). Comparison of blood samples before and after immune checkpoint blockade with prior tumor from one metastatic melanoma patient detected increased T cell receptor beta sharing between tumour and mutant compared to tumour and wild-type or tumour and uncultured: 11.0% (72/656), 1.5% (206/13 639) and 1.3% (381/29 807), respectively (Monte Carlo P = 10~(?7)for mutant versus wild-type and mutant versus uncultured). These data demonstrate that mutant in metastatic melanoma patients are enriched for melanoma-associated T cells and are candidate probes to study in vivo melanoma-reactive T cells.
机译:文本中提供了补充数字内容。该研究检查了来自转移性黑素瘤患者的6-硫代胍抗性T细胞(突变体)是否与类似于类似Thioguanine选择(野生型)的T细胞相比,对黑色素瘤相关的T细胞富集。在转移性黑素瘤患者的5个肿瘤和9个外周血样品上进行黑色素瘤相关抗原五聚体染色。通过在肿瘤进展(n = 8)的转移性黑色素瘤和肿瘤中的血液和肿瘤中突变和肿瘤中的突变物和野生型的突变物和野生型的Sanger测序检查T细胞受体β链条曲目并通过肿瘤衍生的T细胞和未培养的T细胞中的illumina测序(未培养的),免疫检查点延迟之前和之后的血液的野生型和突变体(n = 1)。肿瘤突变体(3/5; P <0.001),但不是血液(0 of 9),与野生型相比,与结合黑色素瘤相关抗原五聚酯相比富集。 T细胞受体β分析肿瘤进展患者(n = 8)检测到突变体中的短生素瘤相关的T细胞与血液中的野生型相比(蒙特卡罗p = 10〜(α7))。在与肿瘤和野生型或肿瘤和未培养的肿瘤和突变体中,免疫检查点延迟之前和之后的血液样本在免疫检查点延迟的血液样本障碍物的增加,检测到肿瘤和突变体之间的增加的T细胞受体β共享:11.0%(72/656),1.5 %(206/13 639)和1.3%(381/29 807)(Monte Carlo P = 10〜(α7)用于突变体与野生型和突变体与未培养的)。这些数据表明转移性黑素瘤患者的突变体富含黑色素瘤相关的T细胞,并且是在体内黑色素瘤反应性T细胞中研究的候选探针。

著录项

  • 来源
    《Melanoma research 》 |2020年第1期| 共10页
  • 作者单位

    University of Wisconsin Carbone Cancer Center University of Wisconsin School of Medicine and;

    University of Wisconsin Carbone Cancer Center University of Wisconsin School of Medicine and;

    Biostatistics and Medical Informatics;

    University of Wisconsin Carbone Cancer Center University of Wisconsin School of Medicine and;

    Department of Biostatistics University of Florida;

    University of Wisconsin Carbone Cancer Center University of Wisconsin School of Medicine and;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学 ;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号